Nurr1 attenuates hepatic stellate cell activation by inhibiting EMT and cell cycle progression via interaction with Smad3
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10896-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Donglin Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 92 Aiguo Road, Nanch…. Hauptthemen laut MEDLINE: Smad3 Protein, Hepatic Stellate Cells, Epithelial-Mesenchymal Transition, Nuclear Receptor Subfamily 4, Group A, Member 2. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province of China, Jiangxi Provincial Health Commission Science and Technology Plan.
Abstract (Originalsprache)
BACKGROUND: Epithelial–mesenchymal transition (EMT) plays a vital role in hepatic fibrosis, as hepatic stellate cells (HSCs) can undergo EMT during liver fibrogenesis. Our previous work indicated that overexpression of the orphan nuclear receptor Nurr1 (NR4A2) can inhibit HSC activation and ameliorate liver fibrosis. However, the underlying mechanism by which Nurr1 affects EMT in hepatic fibrosis remains unclear. METHODS AND RESULTS: HSC-T6 cells were transfected with either a Nurr1 overexpression plasmid or a small interfering RNA targeting Nurr1 to modulate Nurr1 levels. Transforming growth factor β1 (TGF-β1) was used to activate HSC-T6 cells. In vitro analyses showed that Nurr1 overexpression decreased α-smooth muscle actin (α-SMA) levels and increased E-cadherin (E-CAD) levels, whereas Nurr1 knockdown had the opposite effect. Consistently, Nurr1 overexpression reduced mRNA expression of EMT-related genes (α-SMA, Snail, Slug, and Smad3), while Nurr1 silencing elevated their expression. Flow cytometry revealed that Nurr1 overexpression increased the proportion of cells in S phase and reduced the G₂/M population, whereas Nurr1 knockdown also increased S-phase cells but led to accumulation in G₂/M phase. Chromatin immunoprecipitation (ChIP) assays demonstrated a significant enrichment of the Smad3 promoter in Nurr1-immunoprecipitated chromatin, indicating that Nurr1 directly binds to the Smad3 promoter. CONCLUSIONS: Nurr1 suppresses HSC activation by downregulating EMT gene expression and modulating the cell cycle. Our findings suggest that Nurr1 inhibits the fibrogenic activation of HSCs, at least in part through transcriptional repression of EMT drivers (such as Smad3) and induction of S-phase cell cycle arrest.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 92 Aiguo Road, Nanchang, Jiangxi, China.
- Nanchang County People's Hospital, 199 Xiangyang Road, Liantang Town, Nanchang County, Jiangxi Province, China.
- Department of Gastroenterology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 92 Aiguo Road, Nanchang, Jiangxi, China. huangchenzhen@sina.com.
Förderung
- Natural Science Foundation of Jiangxi Province of China
- Jiangxi Provincial Health Commission Science and Technology Plan
Zitieren
APA
Liu, D., Xiong, X., & Chen, P. (2025). Nurr1 attenuates hepatic stellate cell activation by inhibiting EMT and cell cycle progression via interaction with Smad3. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10896-3
Vancouver
Liu D, Xiong X, Chen P. Nurr1 attenuates hepatic stellate cell activation by inhibiting EMT and cell cycle progression via interaction with Smad3. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10896-3
BibTeX
@article{Liu2025,
author = {Liu, Donglin and Xiong, Xinghua and Chen, Pengguo},
title = {Nurr1 attenuates hepatic stellate cell activation by inhibiting EMT and cell cycle progression via interaction with Smad3},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10896-3}
}
EUVIMED